SciELO - Scientific Electronic Library Online

 
vol.20 issue3Therapeutic potential cannabinoidsPain in children and adolescents with neuromuscular diseases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la Sociedad Española del Dolor

Print version ISSN 1134-8046

Abstract

MOYA RIERA, J.; MURILLO GONZALEZ, M.; RODRIGUEZ MESA, D.  and  ESCOBAR ALVAREZ, Y.. Fentanyl for breakthrough cancer pain. Rev. Soc. Esp. Dolor [online]. 2013, vol.20, n.3, pp.137-141. ISSN 1134-8046.  https://dx.doi.org/10.4321/S1134-80462013000300006.

Pain control is an important aspect in the quality of the healthcare. The drug of choice in breakthrough pain control requires potency and a very fast rate of absorption. This speed is a critical aspect. The preparations of fentanyl, because of its great potency, probably are drugs that the clinician should use in patients with breakthrough pain, but not all fentanyl preparations have similar kinetics. The pharmacokinetic properties of fentanyl buccal tablets (FBT) powered by OraVescent® drug delivery technology have shown great speed of absorption, much faster than other preparations of opiates. There is evidence indicating that the preparation of FBT fentanyl is effective in episodes of cancer breakthrough pain. Fentanyl FTB has also shown efficacy in breakthrough pain not related to cancer.

Keywords : Fentanyl; Breakthrough pain; Cancer.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License